Compare Danaher Corporation (DHR) vs Dow Inc (DOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Dow Inc — how do they compare? Danaher Corporation trades at $220.43 (market cap $152.87B), while Dow Inc trades at $28.55 (market cap $20.65B). The key difference: Danaher Corporation is far larger — about 7.4× Dow Inc's market cap, and Dow Inc pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Dow Inc for 82 Days on average.
| DHR | DOW | |
|---|---|---|
Market Cap | $152.87B | $20.65B |
Volume | 5,228,698 | 14,126,943 |
Sector | Health | Basic Materials |
52-Week High | $242.05 | $41.87 |
52-Week Low | $161.91 | $20.65 |
Typical Hold Time | 69 Days | 82 Days |
Enterprise Value | $175.08B | $36.34B |
Dividend Yield | 0.74% | 4.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
DOW trades at $28.80, up 3.71% today, near the analyst low target of $28.00. The stock shows a bullish technical signal despite negative profitability, with ROE at -7.86% and net income margin at -3.13%. Recent earnings have beaten expectations, but revenue declined to $39.97B in 2025. Cash flow improved to $1.69B net in 2025, though operating cash flow remains pressured.
Outlook is mixed: analyst consensus is a hold with a $34.22 price target, implying 19% upside, but weak margins and declining revenue pose risks. The dividend yield offers income support, but investors face headwinds from cyclical chemical demand and high debt levels, with debt-to-asset ratio rising to 29.87% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
